A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2019
Price : $35 *
At a glance
- Drugs Piclidenoson (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms ACROBAT
- Sponsors Can-Fite BioPharma
- 22 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 22 May 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2020.
- 31 Aug 2018 Biomarkers information updated